macimorelin (Macrilen) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class
AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Macimorelin (AEZS 130) is an orally active, small-molecule, peptidomimetic growth hormone secretagogue receptor (GHSR1A) agonist (ghrelin analogue), being developed by AEterna Zentaris for the diagnosis of adult growth hormone deficiency (AGHD; somatotropin deficiency), and for the treatment of cachexia associated with chronic disease such as AIDS and cancer. Macimorelin was approved by the FDA in December 2017 under the market name Macrilen for oral solution. Macimorelin stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus. Macimorelin has been granted orphan drug designation by the FDA for diagnosis of AGHD.   NCATS

Chemistry

  • SMILES: CC(=O)O.CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O
  • InChIKey: WVDSKQXKCDZXLH-OHIDFYLOSA-N
  • Mol. Mass: 534.62
  • ALogP: 1.84
  • ChEMBL Molecules:
    macimorelin acetate  
    macimorelin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$56.1407 - $73.8693
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

aezs-130 | aib-dtrp-dgtrp-cho | aib-trp-gtrp-cho | aminoisobutyryl-tryptophyl-tryptophanamine-formyl | ard-07 | ep-01572 | ep1572 | ep 1572 | ep-1572 | jmv1843 | jmv 1843 | jmv-1843 | macimorelin | macimorelin acetate

Organizations (9)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Dwarfism, Pituitary (approved 2017)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Cachexia (Phase 2)

Growth Hormone (Phase 3)

Healthy Volunteers (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue